Semin Reprod Med 2022; 40(01/02): 032-041
DOI: 10.1055/s-0041-1736337
Review Article

Female Hyperandrogenism in Elite Sports and the Athletic Triad

1   Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
2   Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden
› Author Affiliations

Abstract

Essential hyperandrogenism seems to be overrepresented in female elite athletes. This applies to mild forms such as polycystic ovary syndrome, as well as rare differences/disorders of sex development (DSD). The reason is likely a selection bias since there is increasing evidence that androgens are beneficial for athletic performance by potent anabolic effects on muscle mass and bone mass, and stimulation of erythropoiesis. XY DSD may cause a greatly increased production of testosterone in the male range, that is, 10 to 20 times higher than the normal female range. The established regulations concerning the eligibility of female athletes with severe hyperandrogenism to compete in the female classification remain controversial. The most common cause of menstrual disorders in female athletes, however, is probably an acquired functional hypothalamic disturbance due to energy deficiency in relation to energy expenditure, which could lead to low bone mineral density and increased risk of injury. This condition is particularly common in endurance and esthetic sports, where a lean body composition is considered an advantage for physical performance. It is important to carefully evaluate endocrine disturbances and menstrual disorders in athletes since the management should be specific according to the underlying cause.



Publication History

Article published online:
11 October 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Azziz R, Carmina E, Chen Z. et al. Polycystic ovary syndrome. Nat Rev Dis Primers 2016; 2: 16057
  • 2 Handelsman DJ, Hirschberg AL, Bermon S. Circulating testosterone as the hormonal basis of sex differences in athletic performance. Endocr Rev 2018; 39 (05) 803-829
  • 3 Hirschberg AL. Female hyperandrogenism and elite sport. Endocr Connect 2020; 9: R81-R92
  • 4 Constantini NW, Warren MP. Menstrual dysfunction in swimmers: a distinct entity. J Clin Endocrinol Metab 1995; 80 (09) 2740-2744
  • 5 Rickenlund A, Carlström K, Ekblom B, Brismar TB, von Schoultz B, Hirschberg AL. Hyperandrogenicity is an alternative mechanism underlying oligomenorrhea or amenorrhea in female athletes and may improve physical performance. Fertil Steril 2003; 79 (04) 947-955
  • 6 Rickenlund A, Thorén M, Carlström K, von Schoultz B, Hirschberg AL. Diurnal profiles of testosterone and pituitary hormones suggest different mechanisms for menstrual disturbances in endurance athletes. J Clin Endocrinol Metab 2004; 89 (02) 702-707
  • 7 Hagmar M, Berglund B, Brismar K, Hirschberg AL. Hyperandrogenism may explain reproductive dysfunction in Olympic athletes. Med Sci Sports Exerc 2009; 41 (06) 1241-1248
  • 8 Dadgostar H, Razi M, Aleyasin A, Alenabi T, Dahaghin S. The relation between athletic sports and prevalence of amenorrhea and oligomenorrhea in Iranian female athletes. Sports Med Arthrosc Rehabil Ther Technol 2009; 1 (01) 16
  • 9 Eliakim A, Marom N, Galitskaya L, Nemet D. Hyperandrogenism among elite adolescent female athletes. J Pediatr Endocrinol Metab 2010; 23 (08) 755-758
  • 10 Coste O, Paris F, Galtier F, Letois F, Maïmoun L, Sultan C. Polycystic ovary-like syndrome in adolescent competitive swimmers. Fertil Steril 2011; 96 (04) 1037-1042
  • 11 Javed A, Kashyap R, Lteif AN. Hyperandrogenism in female athletes with functional hypothalamic amenorrhea: a distinct phenotype. Int J Womens Health 2015; 7: 103-111
  • 12 Łagowska K, Kapczuk K. Testosterone concentrations in female athletes and ballet dancers with menstrual disorders. Eur J Sport Sci 2016; 16 (04) 490-497
  • 13 Koltun KJ, Williams NI, Scheid JL, De Souza MJ. Discriminating hypothalamic oligomenorrhea/amenorrhea from hyperandrogenic oligomenorrhea/amenorrhea in exercising women. Appl Physiol Nutr Metab 2020; 45 (07) 707-714
  • 14 Hirschberg AL. Polycystic ovary syndrome, obesity and reproductive implications. Womens Health (Lond) 2009; 5 (05) 529-540 , quiz 541–542
  • 15 Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2019; 3: CD007506
  • 16 Kogure GS, Silva RC, Picchi Ramos FK. et al. Women with polycystic ovary syndrome have greater muscle strength irrespective of body composition. Gynecol Endocrinol 2015; 31 (03) 237-242
  • 17 Kogure GS, Silva RC, Miranda-Furtado CL. et al. Hyperandrogenism enhances muscle strength after progressive resistance training, independent of body composition, in women with polycystic ovary syndrome. J Strength Cond Res 2018; 32 (09) 2642-2651
  • 18 Kogure GS, Ribeiro VB, Gennaro FGO, Ferriani RA, Miranda-Furtado CL, Reis RMD. Physical performance regarding handgrip strength in women with polycystic ovary syndrome. Rev Bras Ginecol Obstet 2020; 42 (12) 811-819
  • 19 Caliskan Guzelce E, Eyupoglu D, Torgutalp S. et al. Is muscle mechanical function altered in polycystic ovary syndrome?. Arch Gynecol Obstet 2019; 300 (03) 771-776
  • 20 Ginsburg GS, O'Toole M, Rimm E, Douglas PS, Rifai N. Gender differences in exercise-induced changes in sex hormone levels and lipid peroxidation in athletes participating in the Hawaii Ironman triathlon. Ginsburg-gender and exercise-induced lipid peroxidation. Clin Chim Acta 2001; 305 (1-2): 131-139
  • 21 Berg U, Enqvist JK, Mattsson CM. et al. Lack of sex differences in the IGF-IGFBP response to ultra endurance exercise. Scand J Med Sci Sports 2008; 18 (06) 706-714
  • 22 Li CY, Hsu G-S, Suzuki K, Ko MH, Fang SH. Salivary immuno factors, cortisol and testosterone responses in athletes of a competitive 5,000 m race. Chin J Physiol 2015; 58 (04) 263-269
  • 23 Monje C, Rada I, Castro-Sepulveda M, Peñailillo L, Deldicque L, Zbinden-Foncea H. Effects of a high intensity interval session on mucosal immune function and salivary hormones in male and female endurance athletes. J Sports Sci Med 2020; 19 (02) 436-443
  • 24 Enea C, Boisseau N, Ottavy M. et al. Effects of menstrual cycle, oral contraception, and training on exercise-induced changes in circulating DHEA-sulphate and testosterone in young women. Eur J Appl Physiol 2009; 106 (03) 365-373
  • 25 Edwards DA, Kurlander LS. Women's intercollegiate volleyball and tennis: effects of warm-up, competition, and practice on saliva levels of cortisol and testosterone. Horm Behav 2010; 58 (04) 606-613
  • 26 O'Leary CB, Lehman C, Koltun K, Smith-Ryan A, Hackney AC. Response of testosterone to prolonged aerobic exercise during different phases of the menstrual cycle. Eur J Appl Physiol 2013; 113 (09) 2419-2424
  • 27 Cook CJ, Crewther BT, Kilduff LP, Agnew LL, Fourie P, Serpell BG. Testosterone and dihydrotestosterone changes in male and female athletes relative to training status. Int J Sports Physiol Perform 2021; 4: 1-7
  • 28 Lee PA, Nordenström A, Houk CP. et al; Global DSD Update Consortium. Global disorders of sex development update since 2006: perceptions, approach and care. Horm Res Paediatr 2016; 85 (03) 158-180
  • 29 Bermon S, Garnier PY, Hirschberg AL. et al. Serum androgen levels in elite female athletes. J Clin Endocrinol Metab 2014; 99 (11) 4328-4335
  • 30 Karkazis K, Jordan-Young R, Davis G, Camporesi S. Out of bounds? A critique of the new policies on hyperandrogenism in elite female athletes. Am J Bioeth 2012; 12 (07) 3-16
  • 31 Bermon S, Ritzén M, Hirschberg AL, Murray TH. Are the new policies on hyperandrogenism in elite female athletes really out of bounds? Response to “out of bounds? A critique of the new policies on hyperandrogenism in elite female athletes”. Am J Bioeth 2013; 13 (05) 63-65
  • 32 Ritzén M, Ljungqvist A, Budgett R. et al. The regulations about eligibility for women with hyperandrogenism to compete in women's category are well founded. A rebuttal to the conclusions by Healy et al. Clin Endocrinol (Oxf) 2015; 82 (02) 307-308
  • 33 Sonksen P, Ferguson-Smith MA, Bavington LD. et al. Medical and ethical concerns regarding women with hyperandrogenism and elite sport. J Clin Endocrinol Metab 2015; 100 (03) 825-827
  • 34 Allen DB. Hormonal eligibility criteria for ‘includes females’ competition: a practical but problematic solution. Horm Res Paediatr 2016; 85 (04) 278-282
  • 35 The International Associations of Athletics Federations. Eligibility regulations for the female classification (athletes with differences of sex development). Version 2.0. 2019. Accessed June 1, 2020 at: www.iaaf.org/about-iaaf/documents/rules-regulations
  • 36 Hirschberg AL. Hyperandrogenism in female athletes. J Clin Endocrinol Metab 2019; 104 (02) 503-505
  • 37 Hamilton BR, Lima G, Barrett J. et al. Integrating transwomen and female athletes with differences of sex development (DSD) into elite competition: the FIMS 2021 consensus statement. Sports Med 2021; 51: 1401-1415
  • 38 Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987; 8 (01) 1-28
  • 39 Notelovitz M. Androgen effects on bone and muscle. Fertil Steril 2002; 77 (Suppl. 04) S34-S41
  • 40 Croson R, Gneezy U. Gender differences in preferences. J Econ Lit 2009; 47: 448-474
  • 41 Cardinale M, Stone MH. Is testosterone influencing explosive performance?. J Strength Cond Res 2006; 20 (01) 103-107
  • 42 Crewther BT, Christian C. Relationships between salivary testosterone and cortisol concentrations and training performance in Olympic weightlifters. J Sports Med Phys Fitness 2010; 50 (03) 371-375
  • 43 Bermon S, Garnier PY. Serum androgen levels and their relation to performance in track and field: mass spectrometry results from 2127 observations in male and female elite athletes. Br J Sports Med 2017; 51 (17) 1309-1314
  • 44 Eklund E, Berglund B, Labrie F, Carlström K, Ekström L, Hirschberg AL. Serum androgen profile and physical performance in women Olympic athletes. Br J Sports Med 2017; 51 (17) 1301-1308
  • 45 Bermon S. Androgens and athletic performance of elite female athletes. Curr Opin Endocrinol Diabetes Obes 2017; 24 (03) 246-251
  • 46 Wood RI, Stanton SJ. Testosterone and sport: current perspectives. Horm Behav 2012; 61 (01) 147-155
  • 47 Huang G, Basaria S, Travison TG. et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause 2014; 21 (06) 612-623
  • 48 Hirschberg AL, Elings Knutsson J, Helge T. et al. Effects of moderately increased testosterone concentration on physical performance in young women: a double blind, randomised, placebo controlled study. Br J Sports Med 2020; 54 (10) 599-604
  • 49 Wiik A, Lundberg TR, Rullman E. et al. Muscle strength, size, and composition following 12 months of gender-affirming treatment in transgender individuals. J Clin Endocrinol Metab 2020; 105 (03) e805-e813
  • 50 Manning J, Kilduff L, Cook C, Crewther B, Fink B. Digit ratio (2D:4D): a biomarker for prenatal sex steroids and adult sex steroids in challenge situations. Front Endocrinol (Lausanne) 2014; 5: 9
  • 51 Swift-Gallant A, Johnson BA, Di Rita V, Breedlove SM. Through a glass, darkly: human digit ratios reflect prenatal androgens, imperfectly. Horm Behav 2020; 120: 104686
  • 52 Hönekopp J, Schuster M. A meta-analysis on 2D:4D and athletic prowess: substantial relationships but neither hand out-predicts the other. Personal Individual Diff 2010; 48: 4-10
  • 53 Giffin NA, Kennedy RM, Jones ME, Barber CA. Varsity athletes have lower 2D:4D ratios than other university students. J Sports Sci 2012; 30 (02) 135-138
  • 54 Bennett M, Manning JT, Cook CJ, Kilduff LP. Digit ratio (2D:4D) and performance in elite rugby players. J Sports Sci 2010; 28 (13) 1415-1421
  • 55 Eklund E, Ekström L, Thörngren J-O, Ericsson M, Berglund B, Hirschberg AL. Digit ratio (2D:4D) and physical performance in female Olympic athletes. Front Endocrinol (Lausanne) 2020; 11: 292
  • 56 Mountjoy M, Sundgot-Borgen J, Burke L. et al. The IOC consensus statement: beyond the Female Athlete Triad–Relative Energy Deficiency in Sport (RED-S). Br J Sports Med 2014; 48 (07) 491-497
  • 57 Hagmar M, Hirschberg AL, Berglund L, Berglund B. Special attention to the weight-control strategies employed by Olympic athletes striving for leanness is required. Clin J Sport Med 2008; 18 (01) 5-9
  • 58 Sundgot-Borgen J, Torstveit MK. Aspects of disordered eating continuum in elite high-intensity sports. Scand J Med Sci Sports 2010; 20 (Suppl. 02) 112-121
  • 59 Elliott-Sale KJ, Tenforde AS, Parziale AL, Holtzman B, Ackerman KE. Endocrine effects of relative energy deficiency in sport. Int J Sport Nutr Exerc Metab 2018; 28 (04) 335-349
  • 60 Loucks AB, Mortola JF, Girton L, Yen SS. Alterations in the hypothalamic-pituitary-ovarian and the hypothalamic-pituitary-adrenal axes in athletic women. J Clin Endocrinol Metab 1989; 68 (02) 402-411
  • 61 Laughlin GA, Yen SS. Nutritional and endocrine-metabolic aberrations in amenorrheic athletes. J Clin Endocrinol Metab 1996; 81 (12) 4301-4309
  • 62 Rickenlund A, Thorén M, Nybacka A, Frystyk J, Hirschberg AL. Effects of oral contraceptives on diurnal profiles of insulin, insulin-like growth factor binding protein-1, growth hormone and cortisol in endurance athletes with menstrual disturbance. Hum Reprod 2010; 25 (01) 85-93
  • 63 Ackerman KE, Slusarz K, Guereca G. et al. Higher ghrelin and lower leptin secretion are associated with lower LH secretion in young amenorrheic athletes compared with eumenorrheic athletes and controls. Am J Physiol Endocrinol Metab 2012; 302 (07) E800-E806
  • 64 Loucks AB, Laughlin GA, Mortola JF, Girton L, Nelson JC, Yen SS. Hypothalamic-pituitary-thyroidal function in eumenorrheic and amenorrheic athletes. J Clin Endocrinol Metab 1992; 75 (02) 514-518
  • 65 Yeager KK, Agostini R, Nattiv A, Drinkwater B. The female athlete triad: disordered eating, amenorrhea, osteoporosis. Med Sci Sports Exerc 1993; 25 (07) 775-777
  • 66 Nattiv A, Loucks AB, Manore MM, Sanborn CF, Sundgot-Borgen J, Warren MP. American College of Sports Medicine. American College of Sports Medicine position stand. The female athlete triad. Med Sci Sports Exerc 2007; 39 (10) 1867-1882
  • 67 Skarakis NS, Mastorakos G, Georgopoulos N. et al. Energy deficiency, menstrual disorders, and low bone mineral density in female athletes: a systematic review. Hormones (Athens) 2021; 20 (03) 439-448
  • 68 Mountjoy M, Sundgot-Borgen JK, Burke LM. et al. IOC consensus statement on relative energy deficiency in sport (RED-S): 2018 update. Br J Sports Med 2018; 52 (11) 687-697
  • 69 Adams J, Franks S, Polson DW. et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985; 2 (8469-70): 1375-1379
  • 70 Gordon CM, Ackerman KE, Berga SL. et al. Functional hypothalamic amenorrhea: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2017; 102 (05) 1413-1439
  • 71 Barrack MT, Gibbs JC, De Souza MJ. et al. Higher incidence of bone stress injuries with increasing female athlete triad-related risk factors: a prospective multisite study of exercising girls and women. Am J Sports Med 2014; 42 (04) 949-958
  • 72 Łagowska K, Kapczuk K, Jeszka J. Nine-month nutritional intervention improves restoration of menses in young female athletes and ballet dancers. J Int Soc Sports Nutr 2014; 11 (01) 52
  • 73 De Souza MJ, Nattiv A, Joy E. et al; Female Athlete Triad Coalition, American College of Sports Medicine, American Medical Society for Sports Medicine, American Bone Health Alliance. 2014 Female Athlete Triad Coalition consensus statement on treatment and return to play of the female athlete triad: 1st International Conference held in San Francisco, CA, May 2012, and 2nd International Conference held in Indianapolis, IN, May 2013. Clin J Sport Med 2014; 24 (02) 96-119
  • 74 Misra M, Katzman D, Miller KK. et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 2011; 26 (10) 2430-2438
  • 75 Rickenlund A, Eriksson MJ, Schenck-Gustafsson K, Hirschberg AL. Amenorrhea in female athletes is associated with endothelial dysfunction and unfavorable lipid profile. J Clin Endocrinol Metab 2005; 90 (03) 1354-1359
  • 76 Teede HJ, Misso ML, Costello MF. et al; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018; 110 (03) 364-379
  • 77 Stepto NK, Patten RK, Tassone EC. et al. Exercise recommendations for women with polycystic ovary syndrome: Is the evidence enough?. Sports Med 2019; 49 (08) 1143-1157
  • 78 Rickenlund A, Carlström K, Ekblom B, Brismar TB, Von Schoultz B, Hirschberg AL. Effects of oral contraceptives on body composition and physical performance in female athletes. J Clin Endocrinol Metab 2004; 89 (09) 4364-4370
  • 79 Elliott-Sale KJ, McNulty KL, Ansdell P. et al. The effects of oral contraceptives on exercise performance in women: a systematic review and meta-analysis. Sports Med 2020; 50 (10) 1785-1812
  • 80 Cools M, Nordenström A, Robeva R. et al; COST Action BM1303 working group 1. Caring for individuals with a difference of sex development (DSD): a Consensus Statement. Nat Rev Endocrinol 2018; 14 (07) 415-429